Cargando…
The Choice Between Advanced Therapies for Parkinson’s Disease Patients: Why, What, and When?
When oral dopaminergic medication falls short in the treatment of Parkinson’s disease, patients are left with motor response fluctuations and dyskinesias that may have a large impact on functioning in daily life. They may benefit from one of the currently available advanced treatments, namely deep b...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
IOS Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7592668/ https://www.ncbi.nlm.nih.gov/pubmed/32651333 http://dx.doi.org/10.3233/JPD-202104 |
_version_ | 1783601232431022080 |
---|---|
author | Dijk, Joke M. Espay, Alberto J. Katzenschlager, Regina de Bie, Rob M.A. |
author_facet | Dijk, Joke M. Espay, Alberto J. Katzenschlager, Regina de Bie, Rob M.A. |
author_sort | Dijk, Joke M. |
collection | PubMed |
description | When oral dopaminergic medication falls short in the treatment of Parkinson’s disease, patients are left with motor response fluctuations and dyskinesias that may have a large impact on functioning in daily life. They may benefit from one of the currently available advanced treatments, namely deep brain stimulation, continuous levodopa-carbidopa intestinal gel, and continuous subcutaneous apomorphine infusion. The indication, choice between the separate advanced treatments and the timing can be challenging and will be discussed against the background of the progressive nature of the disease, the heterogeneity of disease manifestation and variable patient characteristics. |
format | Online Article Text |
id | pubmed-7592668 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | IOS Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-75926682020-10-30 The Choice Between Advanced Therapies for Parkinson’s Disease Patients: Why, What, and When? Dijk, Joke M. Espay, Alberto J. Katzenschlager, Regina de Bie, Rob M.A. J Parkinsons Dis Review When oral dopaminergic medication falls short in the treatment of Parkinson’s disease, patients are left with motor response fluctuations and dyskinesias that may have a large impact on functioning in daily life. They may benefit from one of the currently available advanced treatments, namely deep brain stimulation, continuous levodopa-carbidopa intestinal gel, and continuous subcutaneous apomorphine infusion. The indication, choice between the separate advanced treatments and the timing can be challenging and will be discussed against the background of the progressive nature of the disease, the heterogeneity of disease manifestation and variable patient characteristics. IOS Press 2020-09-01 /pmc/articles/PMC7592668/ /pubmed/32651333 http://dx.doi.org/10.3233/JPD-202104 Text en © 2020 – IOS Press and the authors. All rights reserved https://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) License (https://creativecommons.org/licenses/by-nc/4.0/) , which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Dijk, Joke M. Espay, Alberto J. Katzenschlager, Regina de Bie, Rob M.A. The Choice Between Advanced Therapies for Parkinson’s Disease Patients: Why, What, and When? |
title | The Choice Between Advanced Therapies for Parkinson’s Disease Patients: Why, What, and When? |
title_full | The Choice Between Advanced Therapies for Parkinson’s Disease Patients: Why, What, and When? |
title_fullStr | The Choice Between Advanced Therapies for Parkinson’s Disease Patients: Why, What, and When? |
title_full_unstemmed | The Choice Between Advanced Therapies for Parkinson’s Disease Patients: Why, What, and When? |
title_short | The Choice Between Advanced Therapies for Parkinson’s Disease Patients: Why, What, and When? |
title_sort | choice between advanced therapies for parkinson’s disease patients: why, what, and when? |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7592668/ https://www.ncbi.nlm.nih.gov/pubmed/32651333 http://dx.doi.org/10.3233/JPD-202104 |
work_keys_str_mv | AT dijkjokem thechoicebetweenadvancedtherapiesforparkinsonsdiseasepatientswhywhatandwhen AT espayalbertoj thechoicebetweenadvancedtherapiesforparkinsonsdiseasepatientswhywhatandwhen AT katzenschlagerregina thechoicebetweenadvancedtherapiesforparkinsonsdiseasepatientswhywhatandwhen AT debierobma thechoicebetweenadvancedtherapiesforparkinsonsdiseasepatientswhywhatandwhen AT dijkjokem choicebetweenadvancedtherapiesforparkinsonsdiseasepatientswhywhatandwhen AT espayalbertoj choicebetweenadvancedtherapiesforparkinsonsdiseasepatientswhywhatandwhen AT katzenschlagerregina choicebetweenadvancedtherapiesforparkinsonsdiseasepatientswhywhatandwhen AT debierobma choicebetweenadvancedtherapiesforparkinsonsdiseasepatientswhywhatandwhen |